Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers

Nozomi Niitsu, Miyuki Hayama, Tadashi Yoshino, Shigeo Nakamura, Jun Ichi Tamaru, Hirokazu Nakamine, Masataka Okamoto

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Peripheral T-cell lymphoma (PTCL) has a poorer prognosis than diffuse large B-cell lymphoma (DLBCL). We administered the CyclOBEAP regimen (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) to patients with DLBCL, and reported its safety and efficacy. Here, we report the results of a multicentre phase II study of the CyclOBEAP regimen in patients with PTCL. In addition, NME1 remained a prognostic factor for survival, as shown in patients who were treated with CyclOBEAP. There were 84 eligible patients and the median age was 54years. The 5-year overall survival (OS) rate was 72% and progression-free survival (PFS) rate was 61%. The 5-year OS was 93% among the anaplastic large-cell lymphoma cases, 74% among the angioimmunoblastic T-cell lymphoma cases, and 63% among the cases of PTCL-not otherwise specified. When the patients were divided according to the International Prognostic Index or Prognostic Index for PTCL, the 5-year OS and PFS rates did not significantly differ among the risk groups. Positivity for NME1 was found to be a significant independent prognostic factor. Grade 4 neutropenia was observed in 80 patients and thrombocytopenia in nine patients. Our results suggest that the CyclOBEAP therapy is safe and effective for PTCLs. Furthermore, the NME1 protein may be an important prognostic factor in PTCL.

Original languageEnglish
Pages (from-to)582-588
Number of pages7
JournalBritish Journal of Haematology
Volume153
Issue number5
DOIs
Publication statusPublished - Jun 2011
Externally publishedYes

Fingerprint

Peripheral T-Cell Lymphoma
Biomarkers
Survival Rate
Lymphoma, Large B-Cell, Diffuse
Disease-Free Survival
Survival
Anaplastic Large-Cell Lymphoma
T-Cell Lymphoma
Bleomycin
Vincristine
Etoposide
Prednisolone
Neutropenia
Thrombocytopenia
Doxorubicin
Cyclophosphamide
Safety

Keywords

  • Chemotherapy
  • Peripheral T-cell lymphoma
  • Prognostic factor

ASJC Scopus subject areas

  • Hematology

Cite this

Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers. / Niitsu, Nozomi; Hayama, Miyuki; Yoshino, Tadashi; Nakamura, Shigeo; Tamaru, Jun Ichi; Nakamine, Hirokazu; Okamoto, Masataka.

In: British Journal of Haematology, Vol. 153, No. 5, 06.2011, p. 582-588.

Research output: Contribution to journalArticle

Niitsu, Nozomi ; Hayama, Miyuki ; Yoshino, Tadashi ; Nakamura, Shigeo ; Tamaru, Jun Ichi ; Nakamine, Hirokazu ; Okamoto, Masataka. / Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers. In: British Journal of Haematology. 2011 ; Vol. 153, No. 5. pp. 582-588.
@article{9c8702dc92bb469891bc774729228e9e,
title = "Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers",
abstract = "Peripheral T-cell lymphoma (PTCL) has a poorer prognosis than diffuse large B-cell lymphoma (DLBCL). We administered the CyclOBEAP regimen (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) to patients with DLBCL, and reported its safety and efficacy. Here, we report the results of a multicentre phase II study of the CyclOBEAP regimen in patients with PTCL. In addition, NME1 remained a prognostic factor for survival, as shown in patients who were treated with CyclOBEAP. There were 84 eligible patients and the median age was 54years. The 5-year overall survival (OS) rate was 72{\%} and progression-free survival (PFS) rate was 61{\%}. The 5-year OS was 93{\%} among the anaplastic large-cell lymphoma cases, 74{\%} among the angioimmunoblastic T-cell lymphoma cases, and 63{\%} among the cases of PTCL-not otherwise specified. When the patients were divided according to the International Prognostic Index or Prognostic Index for PTCL, the 5-year OS and PFS rates did not significantly differ among the risk groups. Positivity for NME1 was found to be a significant independent prognostic factor. Grade 4 neutropenia was observed in 80 patients and thrombocytopenia in nine patients. Our results suggest that the CyclOBEAP therapy is safe and effective for PTCLs. Furthermore, the NME1 protein may be an important prognostic factor in PTCL.",
keywords = "Chemotherapy, Peripheral T-cell lymphoma, Prognostic factor",
author = "Nozomi Niitsu and Miyuki Hayama and Tadashi Yoshino and Shigeo Nakamura and Tamaru, {Jun Ichi} and Hirokazu Nakamine and Masataka Okamoto",
year = "2011",
month = "6",
doi = "10.1111/j.1365-2141.2011.08634.x",
language = "English",
volume = "153",
pages = "582--588",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers

AU - Niitsu, Nozomi

AU - Hayama, Miyuki

AU - Yoshino, Tadashi

AU - Nakamura, Shigeo

AU - Tamaru, Jun Ichi

AU - Nakamine, Hirokazu

AU - Okamoto, Masataka

PY - 2011/6

Y1 - 2011/6

N2 - Peripheral T-cell lymphoma (PTCL) has a poorer prognosis than diffuse large B-cell lymphoma (DLBCL). We administered the CyclOBEAP regimen (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) to patients with DLBCL, and reported its safety and efficacy. Here, we report the results of a multicentre phase II study of the CyclOBEAP regimen in patients with PTCL. In addition, NME1 remained a prognostic factor for survival, as shown in patients who were treated with CyclOBEAP. There were 84 eligible patients and the median age was 54years. The 5-year overall survival (OS) rate was 72% and progression-free survival (PFS) rate was 61%. The 5-year OS was 93% among the anaplastic large-cell lymphoma cases, 74% among the angioimmunoblastic T-cell lymphoma cases, and 63% among the cases of PTCL-not otherwise specified. When the patients were divided according to the International Prognostic Index or Prognostic Index for PTCL, the 5-year OS and PFS rates did not significantly differ among the risk groups. Positivity for NME1 was found to be a significant independent prognostic factor. Grade 4 neutropenia was observed in 80 patients and thrombocytopenia in nine patients. Our results suggest that the CyclOBEAP therapy is safe and effective for PTCLs. Furthermore, the NME1 protein may be an important prognostic factor in PTCL.

AB - Peripheral T-cell lymphoma (PTCL) has a poorer prognosis than diffuse large B-cell lymphoma (DLBCL). We administered the CyclOBEAP regimen (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) to patients with DLBCL, and reported its safety and efficacy. Here, we report the results of a multicentre phase II study of the CyclOBEAP regimen in patients with PTCL. In addition, NME1 remained a prognostic factor for survival, as shown in patients who were treated with CyclOBEAP. There were 84 eligible patients and the median age was 54years. The 5-year overall survival (OS) rate was 72% and progression-free survival (PFS) rate was 61%. The 5-year OS was 93% among the anaplastic large-cell lymphoma cases, 74% among the angioimmunoblastic T-cell lymphoma cases, and 63% among the cases of PTCL-not otherwise specified. When the patients were divided according to the International Prognostic Index or Prognostic Index for PTCL, the 5-year OS and PFS rates did not significantly differ among the risk groups. Positivity for NME1 was found to be a significant independent prognostic factor. Grade 4 neutropenia was observed in 80 patients and thrombocytopenia in nine patients. Our results suggest that the CyclOBEAP therapy is safe and effective for PTCLs. Furthermore, the NME1 protein may be an important prognostic factor in PTCL.

KW - Chemotherapy

KW - Peripheral T-cell lymphoma

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=79955725824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955725824&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08634.x

DO - 10.1111/j.1365-2141.2011.08634.x

M3 - Article

C2 - 21492124

AN - SCOPUS:79955725824

VL - 153

SP - 582

EP - 588

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -